

---

# 5.30.007

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	December 7, 2011
<b>Subject:</b>	Increlex	<b>Page:</b>	1 of 4

---

**Last Review Date:** September 6, 2024

---

## Increlex

### Description

#### Increlex (mecasermin)

---

#### Background

The active ingredient of Increlex is identical to the natural hormone, insulin-like growth factor-1 (IGF-1), which the body produces in response to stimulation by growth hormone. Without adequate IGF-1, children cannot achieve height within the normal range. Insulin-like growth factor-1 is a key hormonal mediator on statural growth (1).

If insulin-like growth factor-1 deficiency (IGFD) is determined to be primary and severe, treatment with Increlex may help improve the child's growth. Severe Primary IGFD is defined by height standard deviation score  $\leq -3.0$  and basal IGF-1 standard deviation score  $\leq -3.0$  and normal or elevated growth hormone (GH). Severe Primary IGFD includes classical and other forms of growth hormone insensitivity. Patients with Primary IGFD may have mutations in the GH receptor (GHR), post-GHR signaling pathway including the IGF-1 gene. They are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment (1).

#### Regulatory Status

FDA-approved indication: Increlex is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH (1).

#### Limitations of Use:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	December 7, 2011
<b>Subject:</b>	Increlex	<b>Page:</b>	2 of 4

---

Increlex is not a substitute for GH for approved GH indications (1).

Increlex is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory corticosteroids. Thyroid and nutritional deficiencies should be corrected before initiating Increlex treatment. Increlex is not a substitute for GH treatment. Thus, Increlex treatment should be monitored by physicians who are experienced in the diagnosis and management of patients with growth disorders (1).

Increlex is contraindicated in patients with active or suspected neoplasia. Therapy should be discontinued if evidence of malignancy develops. Increlex is contraindicated in patients with closed epiphyses. Intravenous administration of Increlex is contraindicated (1).

Safety and effectiveness in pediatric patients below the age of 2 years of age have not been established (1).

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Increlex may be considered **medically necessary** if the conditions indicated below are met.

Increlex may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 2 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Severe primary insulin-like growth factor-1 (IGF-1) deficiency
  - a. Height standard deviation score  $\leq -3.0$
  - b. Basal IGF-1 standard deviation score  $\leq -3.0$
  - c. Normal or elevated growth hormone (GH)

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	December 7, 2011
<b>Subject:</b>	Increlex	<b>Page:</b>	3 of 4

---

2. Growth Hormone (GH) gene deletion
  - a. Developed neutralizing antibodies to growth hormone (GH)

**AND ALL** of the following:

1. Open epiphyses
2. **NO** evidence of active tumor or neoplasm
3. **NOT** for intravenous administration

---

## Prior – Approval *Renewal* Requirements

Same as above

### Policy Guidelines

## Pre - PA Allowance

None

## Prior - Approval Limits

**Duration** 12 months

---

## Prior - Approval *Renewal* Limits

Same as above

### Rationale

#### Summary

Increlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Increlex is not a substitute for GH for approved GH indications. Increlex is contraindicated in patients with active or suspected neoplasia. Therapy should be discontinued if evidence of malignancy develops. Increlex is contraindicated in patients with closed epiphyses. Intravenous administration of Increlex is contraindicated. Safety and effectiveness in pediatric patients below the age of 2 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Increlex while maintaining optimal therapeutic outcomes.

#### References

1. Increlex [package insert]. Basking Ridge, NJ: Ipsen Biopharmaceuticals Inc.; March 2024.

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Endocrine and Metabolic Drugs	<b>Original Policy Date:</b>	December 7, 2011
<b>Subject:</b>	Increlex	<b>Page:</b>	4 of 4

---

## Policy History

Date	Action
December 2011	New policy based on sole product rhIGF-1 product commercially available. Another product branded as Iplex was discontinued in July 2009 and no claims were submitted in 2009
December 2012	Annual policy review-no change in policy statement and editorial updates
June 2014	Annual editorial review and reference update
September 2015	Annual review and reference update
September 2016	Annual editorial review and reference update Policy number change from 5.08.13 to 5.30.07
December 2017	Annual editorial review and reference update
November 2018	Annual review and reference update
December 2019	Annual review and reference update
December 2020	Annual review and reference update
June 2021	Annual review
June 2022	Annual review
June 2023	Annual review. Changed policy number to 5.30.007
September 2023	Annual review
December 2023	Annual review
June 2024	Annual editorial review and reference update
September 2024	Annual review

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 6, 2024 and is effective on October 1, 2024.**